Aimed at translating our in vitro results to human BC, we evaluated, by IHC, α6β4, ERβ1, ErbB3, and P-AKT expression in 232 primary mammary tumors derived from patients submitted to adjuvant TAM monotherapy. Here, AKT1 is linked to breast cancer.